Vestibular Schwannoma Organoids

January 28, 2026 updated by: Maastricht Radiation Oncology

Vestibular Schwannoma Stem Cell Organoids

In standard of care regularly planned surgery, tissue will be obtained from patients who are suspicious for having vestibular Schwannoma (on MRI). The tissue that remains after the pathologist gathered sufficient for analysis, the remaining tissue is used for creating tumour stem cell organoids.

Study Overview

Status

Completed

Conditions

Detailed Description

This project constitutes scientific research since the presence of tumor stem cells has not been shown in schwannoma before. Secondly the organoid model has not yet been described for VSs. The correlation between effect in schwannoma organoids and in patients has to be evaluated but can proof to be very valuable since it has been shown in a number of tumors. The tumor tissue will be acquired during regularly planned surgery. The tissue that is used is what is left after sufficient material has been sent to the pathologist to make the diagnosis. So the tissue that is used is removed routinely during surgery, but instead of banking it at the pathology department, it is used for the research project. Blood samples that can be used to compare normal DNA to tumor cells DNA will be acquired from central lines that are routinely placed during these procedures, so no additional interventions will be done in acquiring the tissue and blood for this study.

Study Type

Observational

Enrollment (Actual)

100

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Netherlands
    • Limburg
      • Maastricht, Limburg, Netherlands, 6229HX
        • Maastricht University Medical Center
      • Maastricht, Limburg, Netherlands, 6229ET
        • MAASTRO

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients with a supsicion for vestibular schwannoma on an MRI for which surgery was indicated (approximately 10 per year in Maastricht).

Description

Inclusion Criteria:

  • MRI with suspicion for vestibular schwannoma
  • Indication for surgery in the skull base committee
  • 18 years or older

Exclusion Criteria:

  • Refusal to participate
  • Younger than 18 years
  • Incapacitated

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Feasibility
Time Frame: 10 years
Feasibility to create organoids from schwannoma tumour tissue and make a "living" biobank of these tissues in the laboratory to study the resistance mechanisms towards treatments.
10 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Phenotype
Time Frame: 10 years
Comparing the phenotypical profile of the vestibular schwannoma organoid to the phenotypical profile of the original tumour.
10 years
Genetic
Time Frame: 10 years
Comparing the genetic profile of the vestibular schwannoma organoid to the genetic profile of the original tumour.
10 years
Epigenetic
Time Frame: 10 years
Comparing the epigenetic profile of the vestibular schwannoma organoid to the epigenetic profile of the original tumour.
10 years
Proteomic
Time Frame: 10 years
Comparing the proteomic profile of the vestibular schwannoma organoid to the proteomic profile of the original tumour.
10 years
Transcriptomic
Time Frame: 10 years
Comparing the transcriptomic profile of the vestibular schwannoma organoid to the transcriptomic profile of the original tumour.
10 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Maastricht Radiation Oncology

Collaborators

Maastricht University Medical Center

Investigators

  • Principal Investigator: Koos Hovinga, Maastricht University Medical Center
  • Principal Investigator: Marc Vooijs, MD, PhD, MAASTRO

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 1, 2020

Primary Completion (Actual)

January 1, 2026

Study Completion (Actual)

January 1, 2026

Study Registration Dates

First Submitted

March 14, 2023

First Submitted That Met QC Criteria

March 14, 2023

First Posted (Actual)

March 27, 2023

Study Record Updates

Last Update Posted (Actual)

January 30, 2026

Last Update Submitted That Met QC Criteria

January 28, 2026

Last Verified

January 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Schwannoma organoids

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Vestibular Schwannoma

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe